Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 6/20 | 0.46 |
| ▸ | F13A1 | P00488 | 5/20 | 0.46 |
| ▸ | TGM1 | P22735 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356491 | 0.95 | USP2 (0.55) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL16612394 | 0.87 | USP2 (0.62) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL861278 | 0.85 | USP2 (0.64) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL20066156 | 0.83 | MEN1 (0.49) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL28954182 | 0.83 | MEN1 (0.49) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| Iodide SCHEMBL15174787 | 0.83 | USP2 (0.62) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28133562 | 0.83 | USP2 (0.62) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| Methyl Alcohol SCHEMBL27463839 | 0.83 | USP2 (0.62) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL27893273 | 0.83 | USP2 (0.62) | MEN1KMT2AHPGDUSP2SMN1; SMN2 | |
| SCHEMBL3593622 | 0.82 | MEN1 (0.54) | MEN1KMT2AHPGDUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8852640-B2 | Micelles for delivery of nitric oxide | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-10-07 | — | — | US | disclosed |
| US-20100003338-A1 | Micelles for delivery of nitric oxide | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002450-A2 | MICELLES FOR DELIVERY OF NITRIC OXIDE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003338-A1 | Micelles for delivery of nitric oxide | NOS2, NOS1, NOS3 | MEN1 712/4885KMT2A 3091/4885HPGD 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.